Results 101 to 110 of about 17,710 (254)

Dupilumab-Associated Blepharoconjunctivitis with Giant Papillae

open access: yesInternational Medical Case Reports Journal, 2020
Filippos Vingopoulos, Douglas R Lazzaro New York University School of Medicine, Department of Ophthalmology, New York, NY 10017, USACorrespondence: Douglas R LazzaroNew York University School of Medicine, Department of Ophthalmology, 222 East 41st Street,
Vingopoulos F, Lazzaro DR
doaj  

Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice [PDF]

open access: yes, 2016
Purpose: Acute, severe asthma exacerbations can be difficult to predict and thus prevent. Patients who have frequent exacerbations are of particular concern.
Burden, Anne   +6 more
core   +2 more sources

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel   +5 more
wiley   +1 more source

Dupilumab in children with eosinophilic esophagitis: a retrospective multicenter study

open access: yesBMC Pediatrics
Background Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder characterized by symptoms of esophageal dysfunction and eosinophil-predominant inflammation. Dupilumab is a human monoclonal antibody that targets both IL-4 and IL-13 signaling.
Mohammed Hasosah   +11 more
doaj   +1 more source

Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis [PDF]

open access: yes, 2015
Genetic association studies have identified 21 loci associated with atopic dermatitis risk predominantly in populations of European ancestry. To identify further susceptibility loci for this common, complex skin disease, we performed a meta-analysis of ...
(AAGC), Australian Asthma Genetics Consortium   +152 more
core   +6 more sources

Club Cells in Nasal Epithelial Repair: Insights From an IL‐13‐Induced Inflammatory Model

open access: yesAllergy, EarlyView.
Four inflammatory endotypes of CRSwNP, defined by eosinophil and neutrophil infiltration, show distinct patterns of basal, club, ciliated, and goblet cell expression in nasal epithelium. Using an ALI‐HNECs model, we demonstrate that IL‐13 impairs mucociliary function by promoting club‐to‐goblet cell differentiation while inhibiting club‐to‐ciliated ...
Zhi‐Qun Huang   +13 more
wiley   +1 more source

Dupilumab‐Induced Erythrodermic Psoriasiform Dermatitis in Chronic Actinic Dermatitis: Case Report and Innovative Treatment Approach

open access: yesClinical Case Reports
The off‐label use of dupilumab has proven to be an effective treatment option for severe chronic actinic dermatitis (CAD). We present the first case of CAD presenting with dupilumab‐induced erythrodermic psoriasiform dermatitis.
Joe Khodeir, Maya Habre
doaj   +1 more source

Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis

open access: yesJournal of Dermatological Treatment
Purpose Dupilumab is a widely recommended treatment for moderate-to-severe atopic dermatitis (AD), with known ocular side effects but less frequent cutaneous reactions.Material and methods This case report details a 52-year-old female patient with atopic
C. Grote   +3 more
doaj   +1 more source

“Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps

open access: yesAllergy, EarlyView.
This study aimed to evaluate the feasibility of extending dupilumab dosing intervals in T2‐CRSwNP by assessing how many patients maintain disease control with once‐every‐12‐weeks (Q12W) dosing and comparing clinical characteristics of super‐responders and excellent responders. Tapering of dupilumab to Q12W appears feasible in super‐responding patients.
P. E. Vonk   +13 more
wiley   +1 more source

Unmet Needs in Treatment Escalation for Chronic Spontaneous Urticaria: Findings From the CURE Registry

open access: yesAllergy, EarlyView.
Appropriate treatment escalation improves CSU disease control. However, only about a quarter of patients achieve a complete response, the main goal of CSU treatment. Approximately one‐third of patients clinically eligible for escalation (UCT < 12) do not receive guideline‐recommended treatment escalation and remain symptomatic on their current ...
Pavel Kolkhir   +25 more
wiley   +1 more source

Home - About - Disclaimer - Privacy